Özet:

Depending on the global population growth and increasing demand for healthcare, the role and importance of the health sector in the economy is also increasing. The impact rate of companies producing health products associated with the Covid-19 pandemic, and of companies producing drugs for chronic diseases varies according to the impact rate of companies producing drugs in other product groups. The aim of this study is to identify how the financial performance of the pharmaceutical and healthcare companies in the period of the pandemic was affected and how they managed this process. In this context, this study has studied the effects of Covid-19 pandemic on the financial structure of the pharmaceutical industry in Turkey. In the analysis, EIS Pharmaceuticals, Pharmaceutical and Financial Investments Industry and Trade A.S. The financial statements of his company were analyzed with financial analysis techniques for the period 2019-2020 and compared with the financial performance of Deva Holding, Lokman Hekim Health A.Ş., MLP Health Services A.Ş., Seyitler Chemistry A.Ş. and Turkish Drug A.Ş., which operates in the pharmaceutical and health sector in Borsa Istanbul. According to the findings obtained in the study, the reduction in the health sector during the Covid 19 pandemic period has affected the financial performance of EIS Pharmaceuticals A.S., and the expected increase in sales and profitability has not occurred. Nevertheless, EIS Pharmaceuticals Pharmaceuticals A.S. in the Covid-19 pandemic process has not experienced a serious decline in its financial performance thanks to its activities on sales, costs, stocks, receipts and debt management. In this context, facing disasters and shocks from outside the company, the effective planning and implementation of the corporate management and corporate risk policy plays an important role in the sustainable growth of the companies.

Anahtar Kelimeler: